In this issue:
Ledipasvir + sofosbuvir effective, safe in GT4 HCV
Nomogram predicts HCC in HCV-compensated cirrhosis
HCC recurrence after anti-HCV treatment with all-oral DAAs
Monitor cirrhotics for HCC occurrence after DAAs
No increased risk of HCC recurrence after DAAs
DAAs improve liver function in decompensated cirrhosis
Response-guided therapy feasible in chronic HBV
TDF in HBV-HIV: slow cccDNA decay, persistent viraemia
SVR ameliorates portal hypertension in HCV
Sofosbuvir + daclatasvir treats HCV recurrence
Please login below to download this issue (PDF)